



Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer's Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models.

Phosphatidylserine

Evidence Summary

May promote cognitive function and protect from decline, especially for DHA-enriched phosphatidylserine. It has a good safety profile but has limited bioavailability.

Neuroprotective Benefit: Mixed evidence from clinical trials, and considerable bias in results reporting. Has poor bioavailability and it's unclear how well it gets into the brain.

Aging and related health concerns: No clear rationale or data. One study reported a minor increase in mobility in elderly, but effect can't be clearly tied to phosphatidylserine.

Safety: Well-tolerated with no serious adverse events reported in short trials. May slightly reduce blood pressure. Information on long-term safety is not available.

What are they? Phosphatidylserine (PS) is a class of phospholipids that help to make up the plasma membranes in the brain. Varying the levels and the symmetry of PS in cell membranes (i.e. on the inside or outside of a membrane) can affect signaling pathways that are central for cell survival (e.g. Akt, protein kinase C, and Raf-1) and neuronal synaptic communication [1]. It is comprised of two fatty acids attached to a serine.

PS and other phospholipids are thought to be hydrolyzed before they are absorbed by the gut, although there are claims to suggest otherwise (e.g. [2]). It is also unknown whether PS would be transported intact through the blood and/or able to penetrate the brain [1]. In other words, if PS supplementation increases PS concentration in cell membranes in the brain, the effect is likely to occur via its separate components of serine and the fatty acid (DHA or other).

Neuroprotection: Mixed evidence from clinical trials, and considerable bias in results reporting. Has poor bioavailability and it's unclear how well it gets into the brain.

- 0 meta-analyses or systematic reviews
- over 20 small clinical trials on various formulations in young, old, or impaired adults
- numerous preclinical studies for the rationale

Many clinical trials have reported the effects of PS supplementation, usually up to 6 months duration. In theory, PS supplementation could shift membrane compositions within days, but the effects have not been rigorously studied. Most studies were small and/or poorly designed.

The brain's composition of PS is largely constant throughout life although slight changes in varying directions have been reported in Alzheimer's [3], Parkinson's [4], schizophrenia [5], and aging [6]. However, most PS in the brain is synthesized locally [1] and it is not clear whether PS supplementation will raise levels in the brain. Although one mouse study suggests that PS supplementation could increase brain PS [7], this may have been an indirect effect of the DHA in the PS. The local synthesis of PS is typically done from DHA-phospholipids (phosphatidylcholine and phosphatidylethanolamine) in cell membranes, so by supplying the precursors, DHA supplementation may increase PS levels in neuronal membranes [1].

Multiple small clinical trials have reported that **PS-DHA derived from bovine cortex** could improve cognitive function and sometimes depression in elderly people with dementia, mild cognitive impairment, or age-associated memory impairment. In the largest of these trials, a double-blind trial



from Italy, PS-DHA from bovine cortex (300 mg/d) reportedly improved memory, learning, motivation, and socialization over 3-6 months in 494 patients [8].

Due to concerns of mad-cow disease, the PS-DHA from bovine cortex is no longer available but alternatives have been generated from marine sources. Their composition is different from the bovine-cortex supplements but in one randomized double-blind trial and an open-label follow-up [9, 10], **DHA-enriched PS** from marine sources (e.g. **Vayacog**[®]) for 15 weeks improved some but not most aspects of cognitive function in elderly people with memory impairment. The number of patients who were rated as clinically improved was not significantly different despite a positive trend of 37% of treated patients versus 28% control [9]. Longer treatment (i.e. 30 weeks instead of 15) did not lead to further improvements in cognitive function.

PS derived from soy (PS-soy) has been tested in several clinical trials with varying and unconvincing effects in elderly people with memory complaints. The best designed study reported that PS-soy at 300 or 600 mg/day had no effects over 12 weeks [11]. A couple of uncontrolled studies have reported cognitive benefits [12, 13] but these are unconvincing given that, in another randomized trial, the placebo and treated groups all improved to the same degree [14].

In theory, the effects of DHA-enriched PS could be replicated by DHA/fish-oil given with PS-soy because the molecular components will be separated before reaching the brain. In 6 month RCTs, combined supplements failed to influence cognition or hemodynamics in healthy adults aged 50-70 years with subjective memory deficits [15] but improved scores on 2 of 4 cognitive assays in high-performing elderly women [16].

ApoE4 interactions? Although DHA itself has evidence for interaction with APOE4, little research is available on whether potential PS benefits (whether PS-DHA or other) will vary across E4 carriers vs non-carriers. A couple of rodent studies suggest that apolipoprotein E can affect PS composition of cell membranes [17] but that E4 is similar to E2 or E3 alleles [18].

Aging and related health concerns: No clear rationale or data. One study reported a minor increase in mobility in elderly, but effect can't be clearly tied to phosphatidylserine.

- 0 meta-analyses
- 1 clinical trial on mobility
- 0 preclinical studies on longevity, mortality, etc.



A combination supplement that includes 70 mg of PS (Efalex active 50+) was reported to modestly improve mobility in high-performing elderly women after 6 months of treatment in a randomized double-blind trial [16]. Whether the effect is due to PS is unclear.

The rationale for aging biology effects beyond the brain is weak. Changes with age have been investigated with phosphatidylserine asymmetry across peripheral cell membranes (e.g. [19]) without mention of a loss of PS in cell membranes outside of the brain.

Safety: Well-tolerated with no serious adverse events reported in short trials. May slightly reduce blood pressure. Information on long-term safety is not available.

Small clinical trials suggest that PS supplements are safe in elderly people with minimal side effects other than slightly reduced blood pressure, whether they are DHA-enriched or derived from soy. Longer studies in larger populations are unavailable, whether observational or randomized. Varied and very small clinical studies suggest a possible decrease in cortisol from bovine cortex PS-DHA.

- PS-DHA, eg. Viacog®: Over a 30-week clinical trial, 100-300 mg/d of Viacog® was well-tolerated with no serious adverse effects in elderly people with memory impairment reported. Resting diastolic blood pressure was decreased after 30 weeks in the open-label extension (3.1 mmHg, $p=0.006$) and a slight weight gain was reported (0.7 kg, $p 0.015$). A wide variety of biochemical parameters were unchanged (e.g. cholesterols, bilirubin, glucose, and others).
- PS-soy, in a handful of small clinical studies in elderly people at doses between 100-600 mg/day, had a good safety profile with no adverse effects. In one open-label trial, systolic and diastolic pressure was decreased[12]. Some evidence suggests that PS-soy in combination with exercise could reduce the cortisol response to overtraining or improve exercise capacity [20].

Dosing and Sources: Doses typically range from 100-500 mg/d. Many different formulations of PS are available, enriched with DHA and/or EPA to varying levels or enriched with omega-6 fatty acids and derived from soy. However, any type of PS in combination with DHA is likely to achieve the same effects given the expected pharmacokinetic properties.

- **Vayacog®** is a prescription medical food available in the United States for cognitive impairment, with phosphatidylserine enriched with DHA and EPA. The cognitive effects discussed above



were observed with a dose between 100-300 mg/day. The 300 mg/d dose (100 mg t.i.d.) provided 300 mg PS and 79 mg of DHA and EPA (in a ratio of 3:1 DHA/EPA).

- **Sharp-PS gold** is also a PS enriched with either DHA or EPA/DHA. The clinical report of its use was at 300 mg PS, which includes 37.5 mg of EPA & DHA.
- PS derived from soy has been tested at doses from 300-600 mg/d in clinical trials.
- **Efalex Active 50+** contains 60 mg PS and fish oil 1g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 20mg d-α tocopherol, 1mg folic acid, and 20 µg vitamin B12. Its use for 6 months was reported to improve some cognitive & mobility scores in high-performing elderly women [16].
- Ginkgo biloba complexed with PS was reported in a very small double-blind RCT in young adults to increase calm, memory performance, and speed of memory tasks. Investigators argued that the PS co-administration makes the active components of ginkgo biloba more bioavailable.

Future research: A 2-year clinical trial with DHA-enriched PS is planned in 360 patients with mild cognitive impairment, with outcomes including various cognitive tests, diagnosis of dementia, sleep, and anxiety. The trial is still recruiting now, 2 years into the study and the estimated date of completion has been pushed back from September 2017 to 2019. ([NCT02211560](https://clinicaltrials.gov/ct2/show/study/NCT02211560)). The company running the trial – Enzymotec Ltd was faced with two [class action lawsuits](#) still underway in [2016](#) around its marketing of infant formula.

Search terms

Pubmed:

- phosphatidylserine + aging, brain, soy, positron emission tomography, PET, 'cancer and supplement'
- phosphatidylserine filtered by meta-analysis, systematic review, and clinical trial
- phosphatidylserine + cancer, cardiovascular, hypertension, heart failure with trials filter

References:

1. Kim, H.Y., B.X. Huang, and A.A. Spector, *Phosphatidylserine in the brain: Metabolism and function*. Prog Lipid Res, 2014. 56C: p. 1-18. <http://www.ncbi.nlm.nih.gov/pubmed/24992464>
2. Glade, M.J. and K. Smith, *Phosphatidylserine and the human brain*. Nutrition, 2015. 31(6): p. 781-6. <https://www.ncbi.nlm.nih.gov/pubmed/25933483>



3. Cunnane, S.C., et al., *Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease*. *J. Alzheimers. Dis.*, 2012. 29(3): p. 691-697
4. Fabelo, N., et al., *Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease*. *Mol Med*, 2011. 17(9-10): p. 1107-18. <http://www.ncbi.nlm.nih.gov/pubmed/21717034>
5. Schmitt, A., et al., *Altered thalamic membrane phospholipids in schizophrenia: a postmortem study*. *Biol Psychiatry*, 2004. 56(1): p. 41-5. <http://www.ncbi.nlm.nih.gov/pubmed/15219471>
6. Stommel, A., H.H. Berlet, and H. Debusch, *Buoyant density and lipid composition of purified myelin of aging human brain*. *Mech Ageing Dev*, 1989. 48(1): p. 1-14. <http://www.ncbi.nlm.nih.gov/pubmed/2725072>
7. Ohkubo, T. and Y. Tanaka, *Administration of DHA-PS to aged mice was suitable for increasing hippocampal PS and DHA ratio*. *J Oleo Sci*, 2010. 59(5): p. 247-53. <http://www.ncbi.nlm.nih.gov/pubmed/20431241>
8. Cenacchi, T., et al., *Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration*. *Aging (Milano)*, 1993. 5(2): p. 123-33. <http://www.ncbi.nlm.nih.gov/pubmed/8323999>
9. Vakhapova, V., et al., *Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial*. *Dement Geriatr Cogn Disord*, 2010. 29(5): p. 467-74. <http://www.ncbi.nlm.nih.gov/pubmed/20523044>
10. Vakhapova, V., et al., *Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study*. *Dement Geriatr Cogn Disord*, 2014. 38(1-2): p. 39-45. <http://www.ncbi.nlm.nih.gov/pubmed/24577097>
11. Jorissen, B.L., et al., *The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment*. *Nutr Neurosci*, 2001. 4(2): p. 121-34. <http://www.ncbi.nlm.nih.gov/pubmed/11842880>
12. Richter, Y., et al., *The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study*. *Clin Interv Aging*, 2013. 8: p. 557-63. <http://www.ncbi.nlm.nih.gov/pubmed/23723695>
13. Zanotta, D., S. Puricelli, and G. Bonoldi, *Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study*. *Neuropsychiatr Dis Treat*, 2014. 10: p. 225-30. <http://www.ncbi.nlm.nih.gov/pubmed/24523587>
14. Kato-Kataoka, A., et al., *Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints*. *J Clin Biochem Nutr*, 2010. 47(3): p. 246-55. <http://www.ncbi.nlm.nih.gov/pubmed/21103034>
15. Jackson, P.A., et al., *DHA Supplementation Alone or in Combination with Other Nutrients Does not Modulate Cerebral Hemodynamics or Cognitive Function in Healthy Older Adults*. *Nutrients*, 2016. 8(2): p. 86. <http://www.ncbi.nlm.nih.gov/pubmed/26867200>
16. Strike, S.C., et al., *A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study*. *J Gerontol A Biol Sci Med Sci*, 2016. 71(2): p. 236-42. <https://www.ncbi.nlm.nih.gov/pubmed/26265727>
17. Igbavboa, U., et al., *A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes*. *J Neurochem*, 2002. 80(2): p. 255-61. <http://www.ncbi.nlm.nih.gov/pubmed/11902115>



18. Sharman, M.J., et al., *Profiling brain and plasma lipids in human APOE epsilon2, epsilon3, and epsilon4 knock-in mice using electrospray ionization mass spectrometry*. J Alzheimers Dis, 2010. 20(1): p. 105-111. <http://www.ncbi.nlm.nih.gov/pubmed/20164599>
19. Franco, R.S., et al., *Changes in the properties of normal human red blood cells during in vivo aging*. Am J Hematol, 2013. 88(1): p. 44-51. <https://www.ncbi.nlm.nih.gov/pubmed/23115087>
20. Kingsley, M., *Effects of phosphatidylserine supplementation on exercising humans*. Sports Med., 2006. 36(8): p. 657-669

Disclaimer: Cognitive Vitality Reports® do not provide, and should not be used for, medical advice, diagnosis, or treatment. You should consult with your healthcare providers when making decisions regarding your health. Your use of these reports constitutes your agreement to the [Terms & Conditions](#).

If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or food/drink with neuroprotective properties that warrant in-depth reviews by ADDF's Aging and Alzheimer's Prevention Program, please contact INFO@alzdiscovery.org. To view our official ratings, visit [Cognitive Vitality's Rating page](#).